|Articles|February 12, 2014
Early Phase CRO Chosen for Cell-Based Therapy Diabetes Trial
Clinical program focused on reversing type 1 diabetes symptoms in patients diagnosed within six months of trial initiation
Advertisement
Chula Vista, Calif.-based early phase CRO will undertake DiaVacs, a biotech company testing a Type I diabetes therapy in Phase Ib/IIa trials. The double-blind, placebo-controlled study will begin by first enrolling 10 subjects who are at least 18 years of age with newly diagnosed Type I diabetes (< 6 months from diagnosis). The 15-month study commitment will have the study participants visiting the Profil facility to test DiaVacs proprietary cell-based therapy. Profil specializes in diabetes and obesity trials.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
2
Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters
3
ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma
4
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
5